Thea Supplement: Use of Intracameral Cefuroxime

In 2007, results from the ESCRS Endophthalmitis Prophylaxis Study showed that intracameral cefuroxime significantly reduced the risk of endophthalmitis after cataract surgery [ESCRS Endophthalmitis Study Group. J Cataract Refract. Surg. 2007;33:978-988]. Then in 2012, a major obstacle to systematic intracameral use was eliminated when Aprokam® (cefuroxime 50mg powder for injection; Laboratoires Théa) was approved across Europe as the first and only product indicated for intracameral administration to prevent endophthalmitis after cataract surgery. As of September, 2014, this single-use agent is available in 23 European countries, with approval being sought elsewhere around the world.
Download Supplement
Tags: endophthalmitis
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.